Quantcast
Last updated on April 23, 2014 at 20:10 EDT

Latest biopharmaceutical Stories

2013-05-28 08:29:09

LYNBROOK, N.Y., May 28, 2013 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in-class collagenase-based products marketed as XIAFLEX® in the U.S., today announced that BioSpecifics' President, Tom Wegman, will present a corporate overview at the upcoming Jefferies 2013 Global Healthcare Conference at 10:00 a.m. EDT on Monday, June 3, 2013 in New York, NY. The live webcast of this presentation can be accessed under "Calendar...

2013-05-23 08:27:51

Clinical program supports accelerated approval filing with CFDA in China, and a Phase 3 program in the U.S. SAN DIEGO and SHANGHAI, May 23, 2013 /PRNewswire/ -- Zensun Sci & Tech, Ltd., a biopharmaceutical company based in Shanghai and San Diego, announced today positive results of four completed Phase 2 clinical trials including three double-blind, placebo-controlled studies conducted in China and Australia and interim results from the United States Phase 2 trial for Zensun's...

2013-05-22 08:27:30

SEATTLE, May 22, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, bleeding and disorders of the central nervous system, today announced that Gregory A. Demopulos, M.D., chairman and chief executive officer, is scheduled to present at the following two conferences: 38(th) Annual Deutsche Bank dbAccess Health Care ConferenceMay 29, 20132:10 p.m. EDTBoston, MA Jefferies...

2013-05-21 16:27:26

LA JOLLA, Calif., May 21, 2013 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that Garry E. Menzel, Ph.D., Chief Operating Officer and Executive Vice President, Finance, will present a company overview at the Deutsche Bank 38th Annual Healthcare Conference on Wednesday, May 29, 2013 at 3:30 pm EDT. The conference is being held at the Westin Boston...

2013-05-20 08:27:34

--Demonstration of ASM-024 adjunctive benefit with current treatments in pre-clinical asthma models-- QUEBEC CITY, May 20, 2013 /PRNewswire/ -- Asmacure Ltee, a clinical-stage biopharmaceutical company focused on the development of novel, proprietary compounds that target cholinergic receptors for the treatment of pulmonary diseases, today announced presentations of four studies of ASM-024, Asmacure's lead compound in development for asthma and chronic obstructive pulmonary disease...

2013-05-16 08:28:33

QUEBEC CITY, May 16, 2013 /PRNewswire/ -- Asmacure Ltee, a clinical-stage biopharmaceutical company focused on the development of novel, proprietary compounds that target cholinergic receptors for the treatment of pulmonary diseases, today announced that the company will present four posters at the 2013 American Thoracic Society (ATS) International Conference, taking place May 17-22 in Philadelphia. All four will describe data around ASM-024, Asmacure's lead development compound, currently in...

2013-05-14 08:31:50

SEATTLE, COPENHAGEN, Denmark and SHANGHAI, May 14, 2013 /PRNewswire/ -- CMC Biologics today announced the execution of an agreement with RuiYi Inc. to develop a cell line for RYI-008, a novel anti-IL-6 monoclonal antibody. CMC Biologics' proprietary CHEF1® high-productivity expression plasmid will be utilized for the cell line development to optimize cell growth, and consistent, high-level protein expression in a rapid time frame. Specific terms of the agreement were not disclosed. "We...

2013-05-13 20:22:16

BELLEVILLE, ON, May 13, 2013 /PRNewswire/ - Bioniche Life Sciences Inc. (TSX: BNC) (ASX: BNC), a research-based, technology-driven Canadian biopharmaceutical company, today announced that it has engaged U.S.-based Evercore Partners (Evercore) to assist the Board of Directors and management in its divestment of the Animal Health business. Evercore is a leading independent advisory firm in the U.S. that specializes in merger and acquisition transactions, divestitures and...

2013-05-07 16:29:40

Two oral presentations at EULAR will review the impact of blisibimod on renal biomarkers and improved outcomes in systemic lupus erythematosus (SLE) patients HAYWARD, Calif., May 7, 2013 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company focused on developing and commercializing products to treat autoimmune diseases, today announced that additional data from its Phase 2b PEARL-SC study will be presented in two lecture sessions at the...

2013-05-07 16:29:36

Keryx to Host Investor Conference Call on Wednesday, May 8, 2013 at 8:30am EDT NEW YORK, May 7, 2013 /PRNewswire/ -- Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX), a biopharmaceutical company focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of renal disease (the "Company"), today announced its results for the first quarter ended March 31, 2013. At March 31, 2013, the Company had cash and cash equivalents...